| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 09/12/2002 | US20020127634 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| 09/12/2002 | US20020127612 Cell proliferation polypeptide for use in the diagnosis and treatment of tumors |
| 09/12/2002 | US20020127596 murF2 |
| 09/12/2002 | US20020127595 Endostatin; for use as a contraceptive and in cancer treatment |
| 09/12/2002 | US20020127582 Generating adenovirus-associated vector; obtain cells, transform with expression vector, propagate, recover transformed cells, propagate and recover vectors |
| 09/12/2002 | US20020127567 Nucleotide sequence coding transport protein for use in the diagnosis and treatment of liver disorders |
| 09/12/2002 | US20020127558 Genetic polymorphism of MxA protein and use thereof |
| 09/12/2002 | US20020127553 Apoptin-associating protein |
| 09/12/2002 | US20020127542 Pharmaceutical compositions for treating tumour diseases |
| 09/12/2002 | US20020127272 For use as delivery vehicles for biologically active molecules |
| 09/12/2002 | US20020127246 Use of herpes vectors for tumor therapy |
| 09/12/2002 | US20020127238 Utilizing a modified HIV-1 envelope protein or fragment or DNA encoding a modified HIV-1 envelope protein or fragment, wherein modified protein having a HIV-1 envelope protein V2 region deletion |
| 09/12/2002 | US20020127235 Identification and molecular characterization of proteins, expressed in the Ixodes ricinus salivary glands |
| 09/12/2002 | US20020127217 A polynucleotides which identify and encode Phosphatidylinositol 4,5-bisphosphate 5-phosphatase (polypeptide) |
| 09/12/2002 | US20020127210 Transplants for myocardial scars |
| 09/12/2002 | US20020127209 Tripeptide of intracellular tyrosine-based activation motifs (ITAM) mediates trafficking of targets phagocytosed via Fc gamma RIIA to the lysosomal compartment |
| 09/12/2002 | US20020127204 Improvements in or relating to protection against intracellular infection |
| 09/12/2002 | US20020127199 Novel nucleic acids and polypeptides |
| 09/12/2002 | DE10109855A1 Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung Polypeptide of a p53 protein specific murine alpha / beta T-cell receptor nucleic acids encoding these, and their use |
| 09/12/2002 | DE10109854A1 Polypeptide eines hdm2-Protein spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung Polypeptides of hdm2 protein specific murine alpha / beta T-cell receptor nucleic acids encoding these, and their use |
| 09/12/2002 | DE10109813A1 Tumor-Peptidantigen aus humanem mdm2 Proto-Onkogen Tumor antigen peptide from human MDM2 proto-oncogene |
| 09/12/2002 | CA2445018A1 Tumour peptide antigen produced from human mdm2 proto-oncogene |
| 09/12/2002 | CA2445013A1 Polypeptides of an hdm2 protein-specific murine alpha/beta t-cell receptor, nucleic acids encoding these and their use |
| 09/12/2002 | CA2445004A1 Polypeptides of a p53 protein-specific murine alpha/beta t-cell receptor, nucleic acids encoding these and their use |
| 09/12/2002 | CA2441476A1 Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen |
| 09/12/2002 | CA2440513A1 Nucleic acids for transforming fish cells and methods for their use |
| 09/12/2002 | CA2439934A1 Use of protein histidine phosphatase |
| 09/12/2002 | CA2439628A1 Vaccine |
| 09/12/2002 | CA2439205A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439203A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439200A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439197A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439196A1 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | CA2439195A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439192A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2435277A1 Chimeric polypeptides of serum albumin and uses related thereto |
| 09/12/2002 | CA2434601A1 Methods for specifically inhibiting histone deacetylase-4 |
| 09/12/2002 | CA2432280A1 Novel glutamate receptor modulatory proteins and nucleic acid molecules and uses therefor |
| 09/11/2002 | EP1239042A1 Transposase and method of gene modification |
| 09/11/2002 | EP1239038A1 High-throughput identification of modulators of e2f activity |
| 09/11/2002 | EP1238281A2 Cancer associated antigens and uses therefor |
| 09/11/2002 | EP1238104A2 Agents implicated in endometriosis |
| 09/11/2002 | EP1238092A2 Bovine immunodeficiency virus (biv) based vectors |
| 09/11/2002 | EP1238090A2 Optimized t-dna transfer and vectors therefor |
| 09/11/2002 | EP1238086A1 Method of enhancing immune responses to herpes simplex virus vaccine |
| 09/11/2002 | EP1238084A2 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 09/11/2002 | EP1238082A2 Ifn-alpha homologues |
| 09/11/2002 | EP1238080A2 Bcl-g polypeptides, encoding nucleic acids and methods of use |
| 09/11/2002 | EP1238078A2 Clasp-4 transmembrane protein |
| 09/11/2002 | EP1238077A1 Tnfr/opg-like molecules and uses thereof |
| 09/11/2002 | EP1238075A2 Chordin-like molecules and uses thereof |
| 09/11/2002 | EP1238073A2 A eag gene encoding for a potassium channel |
| 09/11/2002 | EP1238072A2 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| 09/11/2002 | EP1238071A2 Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s rrnas and their uses |
| 09/11/2002 | EP1238070A2 Therapeutically useful synthetic oligonucleotides |
| 09/11/2002 | EP1238066A2 Masp-3, a complement-fixing enzyme, and uses for it |
| 09/11/2002 | EP1237919A1 Interferon-alpha induced gene |
| 09/11/2002 | EP1237918A2 A gene, disrupted in schizophrenia |
| 09/11/2002 | EP1237916A2 Ing2, an iaps associated cell cycle protein, compositions and methods of use |
| 09/11/2002 | EP1237901A1 28 human secreted proteins |
| 09/11/2002 | EP1237582A2 Methods for introducing genes into mammalian subjects |
| 09/11/2002 | EP1237565A1 Betaglycan as an inhibin receptor and uses thereof |
| 09/11/2002 | EP1237541A2 Liposomes |
| 09/11/2002 | EP1098667A4 Chelating systems for use in the delivery of compounds to cells |
| 09/11/2002 | EP0944715B1 Pressure-mediated intracellular delivery of molecules or microparticles |
| 09/11/2002 | EP0808169A4 Programmed cell death genes and proteins |
| 09/11/2002 | EP0769942B1 Use of a cationic amphipathic compound as a transfection agent, vaccine additive or drug |
| 09/11/2002 | EP0762870B1 Virosome-mediated intracellular delivery of therapeutic agents |
| 09/11/2002 | CN1369009A Modified chimeric polyeptides with improved pharmacokinetic properties |
| 09/11/2002 | CN1368885A Compositions and methods for identifying antigens which elicit an immune response |
| 09/11/2002 | CN1368874A Implantable active ingredient depot |
| 09/10/2002 | US6448472 Genetic and epigenetic manipulation of ABC transporters and ectophosphatases for the conference of hormone and herbicide resistance |
| 09/10/2002 | US6448376 Two new proteins which appear to be new members of the e2f gene family, called e2f-5 |
| 09/10/2002 | US6448375 Active and inactive CC-chemokine receptor |
| 09/10/2002 | US6448234 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 09/10/2002 | US6448230 Testis expressed polypeptide |
| 09/10/2002 | US6448223 Antagonists of HMG1 for treating inflammatory conditions |
| 09/10/2002 | US6448093 Solubilization of hyaluronic acid in aqueous solution of electrolyte and acid; solubilization of polar substancec (i.e. a plasmid) in mixture; acidification; dialyzing said mixture to reduce an ionic concentration past point of collapse |
| 09/10/2002 | US6448083 Contacting a mammalian cell with filamentous phage particles presenting a ligand on their surfaces, wherein a vector within the phage encodes a gene product under control of a promoter |
| 09/10/2002 | US6448078 Inhibiting human vpr interacting protein activity in a cell using a nucletide sequence complementary to a portion of the nucleotide sequence that encodes hvip; anticancer agent |
| 09/10/2002 | US6448074 Adeno-associated virus vector for boosting immunogenicity of freshly isolated tumor cells |
| 09/10/2002 | US6448073 Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
| 09/10/2002 | US6448072 Human transcription factor iia (tfiia) is a cellular factor that, together with additional protein components, regulates the expression of human genes |
| 09/10/2002 | US6448070 Recombinant plant viruses, especially their use as immunizing agents which carry antigenic sequences from mammalian or other animal pathogens and their use as a system for increased production of polypeptides of interest |
| 09/10/2002 | US6448045 Expressing a pdx-1 gene in cells that have been cultured under conditions such that the cells are in contact with other cells in the culture; contacting the cells with a glp-1 receptor agonist, thereby inducing insulin gene expression |
| 09/10/2002 | US6448042 These enzymes have been implicated in a variety of disease processes, including tumor cell invasion, tumor angiogenesis and rheumatoid arthritis |
| 09/10/2002 | US6448040 Nucleic acid molecules encoding hypusine mutants having the biological activity, of inhibiting cellular proliferation |
| 09/10/2002 | US6448036 ribB |
| 09/10/2002 | US6448000 Viral growth and cellular genes that function as tumor suppressors. thus, the present invention provides nucleic acids related to and methods of reducing or preventing viral infection or cancer. the invention also provides methods of |
| 09/10/2002 | US6447996 Polypeptides having galanin receptor activity, genetic material for expressing same, any recombinant cell expressing said polypeptides, and the use thereof, are disclosed. |
| 09/10/2002 | US6447993 Protecting cats from infection by a broad range of fiv strains using a multi-subtype fiv vaccine. multi-subtype fiv vaccines comprising either cell free whole virus or cell lines infected with viruses and vaccinating cats |
| 09/10/2002 | US6447784 Genetically engineered salmonella for use in the treatment of cancer |
| 09/10/2002 | US6447776 Monoclonal antibodies against mutant amino acid sequences generated by genetic deletions or point mutations; detection of cancer |
| 09/10/2002 | US6447769 Modified tumor cells to inhibit transforming growth factor |
| 09/10/2002 | US6447768 Methods of gene therapy with a DNA sequence encoding NOS |
| 09/08/2002 | CA2370324A1 Large circular target-specific antisense nucleic acid compounds |
| 09/06/2002 | WO2002068669A2 Matrix attachment regions containing episomal vectors for use in cell-specific gene expression |
| 09/06/2002 | WO2002068654A2 Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus |
| 09/06/2002 | WO2002068653A2 Tri-hybrid melanoma antigen |
| 09/06/2002 | WO2002068650A2 Modified and stabilized gdf propeptides and uses thereof |